Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma

Blood

Volumn 115, Issue 16, 2010, Pages 3416-3417

  Reeder, Craig B ^a   Reece, Donna E ^b   Kukreti, Vishal ^b   Chen, Christine ^b   Trudel, Suzanne ^b   Laumann, Kristina ^c   Hentz, Joseph ^c   Pirooz, Nicholas A ^a   Piza, Jesus G ^b   Tiedemann, Rodger ^a   Mikhael, Joseph R ^a   Bergsagel, Peter L ^a   Leis, Jose F ^a   Fonseca, Rafael ^a   Stewart, Alexander K ^a  

^a MAYO CLINIC   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE;

ADULT; ANEMIA; CLINICAL ASSESSMENT; CLINICAL TRIAL; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; LETTER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; NEUTROPENIA; NEUTROPHIL COUNT; NULL HYPOTHESIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 77951453409     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-02-271676     Document Type: Letter

References (7)

1. Reece DE, Rodriguez GP, Chen C, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol. 2008;26(29):4777-4783.
2. Bladé J, Sampson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115-1123. (Pubitemid 28435189)
3. Reeder C, Reece D, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337-1341.
4. Wang M, Giralt S, Delasalle K, et al. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma. Hematology. 2007;12(3):235-239. (Pubitemid 46930250)
5. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129(6):755-762. (Pubitemid 40904525)
6. Kumar S, Hayman S, Buadi, F, et al. Phase II trial of lenalidomide (Revlimid™) with cyclophosphamide and dexamethasone (RCd) for newly diagnosed myeloma. Blood. 2008;112(11):91a.
7. Richardson P, Lonial S, Jakubowiak A, et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study. Blood. 2008;112(11):92a.